Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.54 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30707816 | 0.90 | MEN1 (0.58) | HRH3POLBHDAC1RAB9AMEN1 | |
| SCHEMBL10953965 | 0.90 | HRH3 (0.88) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL5864236 | 0.85 | HRH3 (0.72) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL3440238 | 0.82 | HRH3 (0.69) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL11434269 | 0.82 | HRH3 (0.69) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL13093982 | 0.82 | HRH3 (0.64) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL25541755 | 0.81 | MEN1 (0.50) | HRH3POLBHDAC1RAB9AMEN1 | |
| SCHEMBL5863714 | 0.81 | POLB (0.93) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL1042778 | 0.81 | HRH3 (0.72) | HRH3POLBHDAC1CXCR4CXCL12 | |
| SCHEMBL21799935 | 0.81 | HRH3 (0.72) | HRH3POLBHDAC1CXCR4CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | HRH3 2194/4885POLB 595/4885HDAC1 818/4885 |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | HRH3 34/4885POLB 3304/4885HDAC1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.